Patents by Inventor James Torchia

James Torchia has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND COMPOSITIONS FOR TREATMENT AND PREVENTION OF CORONAVIRUS INFECTION
    Publication number: 20230272359
    Abstract: The present invention relates, in part, to compositions and methods for treating or preventing coronavirus infection.
    Type: Application
    Filed: July 20, 2021
    Publication date: August 31, 2023
    Inventors: James Torchia, Gordon J. Freeman
  • BISPECIFIC MOLECULES FOR SELECTIVELY MODULATING T CELLS
    Publication number: 20230203157
    Abstract: The present invention relates, in part, to methods for inhibiting activation of T cells in a cell-specific and/or tissue-specific manner, and to bispecific molecules comprising a first part that specifically binds to PD-1 and a second part that specifically binds to a surface antigen of a target cell other than a T cell.
    Type: Application
    Filed: May 27, 2021
    Publication date: June 29, 2023
    Inventors: James Torchia, Gordon J. Freeman
  • Methods for enhancing anti-tumor antibody therapy
    Patent number: 10633450
    Abstract: Methods are provided to enhance the efficacy of antibody therapy directed to tumor cells.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: April 28, 2020
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Holbrook Kohrt, Roch Houot, Ronald Levy, Arash Ash Alizadeh, Matthew J. Goldstein, James Torchia
  • METHODS FOR ENHANCING ANTI-TUMOR ANTIBODY THERAPY
    Publication number: 20180208670
    Abstract: Methods are provided to enhance the efficacy of antibody therapy directed to tumor cells.
    Type: Application
    Filed: August 4, 2017
    Publication date: July 26, 2018
    Inventors: Holbrook Kohrt, Roch Houot, Ronald Levy, Arash Ash Alizadeh, Matthew J. Goldstein, James Torchia
  • Methods for enhancing anti-tumor antibody therapy
    Patent number: 9758589
    Abstract: Methods are provided to enhance the efficacy of antibody therapy directed to tumor cells.
    Type: Grant
    Filed: November 14, 2014
    Date of Patent: September 12, 2017
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Holbrook Kohrt, Roch Houot, Ronald Levy, Arash Ash Alizadeh, Matthew J. Goldstein, James Torchia
  • Methods for Enhancing Anti-Tumor Antibody Therapy
    Publication number: 20160083474
    Abstract: Methods are provided to enhance the efficacy of antibody therapy directed to tumor cells.
    Type: Application
    Filed: November 14, 2014
    Publication date: March 24, 2016
    Inventors: Holbrook Kohrt, Roch Houot, Ronald Levy, Arash Ash Alizadeh, Matthew J. Goldstein, James Torchia
  • Methods for enhancing anti-tumor antibody therapy
    Patent number: 9005619
    Abstract: Methods of enhancing the efficacy of antibody-directed cellular cytotoxicity (ADCC) for therapy directed to killing of tumor cells are disclosed. Cancer specific cell surface antigens are bound by monoclonal antibodies, thereby stimulating a cytotoxic T cell response characterized by an upregulation of cell surface expression of costimulatory molecules on the T cell. The ADCC response is augmented by the subsequent administration of a second antibody that is an agonist of the costimulatory molecule.
    Type: Grant
    Filed: December 7, 2010
    Date of Patent: April 14, 2015
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Holbrook Kohrt, Roch Houot, Ronald Levy, Arash Ash Alizadeh, Matthew J. Goldstein, James Torchia
  • Methods for Enhancing Anti-Tumor Antibody Therapy
    Publication number: 20120321646
    Abstract: Methods of enhancing the efficacy of antibody-directed cellular cytotoxicity (ADCC) for therapy directed to killing of tumor cells are disclosed. Cancer specific cell surface antigens are bound by monoclonal antibodies, thereby stimulating a cytotoxic T cell response characterized by an upregulation of cell surface expression of costimulatory molecules on the T cell. The ADCC response is augmented by the subsequent administration of a second antibody that is an agonist of the costimulatory molecule.
    Type: Application
    Filed: December 7, 2010
    Publication date: December 20, 2012
    Inventors: Holbrook Kohrt, Roch Houot, Ronald Levy, Arash Ash Alizadeh, Matthew J. Goldstein, James Torchia